Ceramide nanoliposomes, compositions and methods of using for immunotherapy
Methods and compositions for treating cancer are provided. Compositions comprising ceramide nanoliposomes are administered to a subject in need of such treatment. The composition administration also enhances immunotherapy. Further administering compositions in combination with tumor antigen specific T-cells, and/or compositions in combination with tumor antigen expressing cells, and/or said compositions in combination with antagonists of PD-1 provides for enhanced results. Administration of the compositions provides for effective treatment of tumors including regression and eradication of established tumors.
1. A method of treating cancer, the method comprising administering to a subject in need of treatment of cancer,
a) a composition comprising ceramide nanoliposome, wherein said ceramide nanoliposome comprises a C6, C8, C10 or C12 ceramide nanoliposome or a combination thereof;
b) a composition selected from the group consisting of:
(i) a composition comprising tumor antigen specific T-cells;
(ii) a composition comprising tumor antigen expressing cells;
(iii) a composition comprising an antagonist of a Programmed Death 1 protein (PD-1); and
(iv) any combination of (i)-(iii),
wherein said compositions of (a) and (b) are administered such that tumor associated macrophages are converted from type M2 to type M1, and wherein immune response in said subject is increased compared to a subject not administered said composition,
thereby treating said cancer.
2. The method of claim 1 , wherein said composition comprising said ceramide nanoliposome is administered prior to administering any one of said compositions of (i)-(iii) or combination thereof.
3. The method of claim 1 , further comprising administering said composition comprising said ceramide nanoliposome more than once prior to administering one or more of said compositions of (i)-(iii) or combination thereof.
4. The method of claim 1 , further comprising administering said composition comprising tumor antigen expressing cells more than once.
5. The method of claim 1 , comprising administering said ceramide nanoliposome, administering said composition comprising tumor antigen specific T-cells, and administering a composition comprising tumor antigen expressing cells.
6. The method of claim 1 , wherein said composition comprising tumor antigen expressing cells comprises cells expressing chimeric antigen receptor T cells (CAR-Ts).
7. The method of claim 1 , wherein said cancer comprises hepatocellular cancer.
8. The method of claim 1 , wherein said ceramide nanoliposome comprises C6 ceramide nanoliposome.
9. A kit comprising
a) a composition comprising ceramide nanoliposome, wherein said ceramide nanoliposome comprises a C6, C8, C10 or C12 ceramide nanoliposome or a combination thereof;
b) a composition selected from the group consisting of:
(i) a composition comprising tumor antigen specific T-cells;
(ii) a composition comprising tumor antigen expressing cells;
(iii) a composition comprising an antagonist of a Programmed Death 1 protein (PD-1); and
(iv) any combination of (i)-(iii);
wherein said kit is administered to a subject in need of treatment of cancer such that tumor associated macrophages are converted from type M2 to type M1, and wherein immune response in said subject is increased compared to a subject not administered said composition.
10. The method of claim 1 comprising administering said composition to a subject having said established cancer tumors.
11. The method of claim 10 , wherein said cancer comprises hepatocellular cancer.
12. The method of claim 10 , wherein said established cancer tumors are eradicated following said administration.
13. A method of increasing immune response by a subject to immunotherapy, the method comprising administering immunotherapy to said subject and administering a composition comprising ceramide nanoliposome, wherein said ceramide nanoliposome comprises a C6, C8, C10 or C12 ceramide nanoliposome or a combination thereof, wherein the immune response of said subject is increased compared to a subject administered said immunotherapy and not administered said compositions comprising said ceramide nanoliposome, and wherein tumor associate macrophages are converted from type M2 to type M1.
14. The method of claim 13 , wherein said immunotherapy is selected from the group consisting of administering a composition comprising tumor antigen specific T-cells, administering a composition comprising tumor antigen expressing cells, administering a composition comprising an antagonist of a Programmed Death 1 protein (PD-1) or a combination thereof.
15. The method of claim 13 , wherein said immunotherapy comprises an antagonist of PD-1 and the number of PD-1 binding sites are decreased after administration of said ceramide nanoliposome and said antagonist of PD-1.
16. A method of increased downregulation of a Programmed Death 1 protein (PD-1) in a subject, the method comprising administering a composition comprising a ceramide nanoliposome, wherein said ceramide nanoliposome comprises a C6, C8, C10 or C12 ceramide nanoliposome or a combination thereof, and wherein PD-1 downregulation is increased compared to a subject not administered said composition.